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2300Medical, West Ryde, New South Wales, Australia). It has been
argued that cuff brachial MBP/DBP should be used in the cali-
bration procedures for radial pressure waveforms to account for the
small brachial-to-radial pressure ampliﬁcation (2). However, cuff
SBP usually underestimates and cuff DBP overestimates the
invasive brachial BP. It is very likely that the calculated cuff MBP
also suffers from a substantial error, no matter whether the 0.33 or
0.4 formula is used. We have demonstrated that whenever the cuff
MBP underestimates the invasive MBP and the cuff DBP over-
estimates the invasive DBP, the pressure waveform calibrated by
cuff MBP/DBP becomes severely compressed and produces a
huge underestimation of the invasive central SBP. Instead, cali-
bration to cuff SBP/DBP produces an acceptable error. We agree
that the potential error in central BP readings might be large and
might compromise the classiﬁcation of patients. However,
noninvasive brachial BP measurements may suffer from the same
error as well (3).
Our study aimed to derive and validate the diagnostic thresholds
of central BP for the diagnosis of hypertension and the corre-
sponding discriminatory power for predicting cardiovascular mor-
tality (1). We didn’t account for the brachial BP in the multivariate
model because we purported to validate the derived central BP
cutoffs for predicting cardiovascular risks. The incorporation of
brachial BP, with its close correlations with central BP, could cause
considerable confusion of the results. However, it is reassuring that,
as shown in the reclassiﬁcation analysis in the Online Table 1 of
our study (1), central BP had an additional contribution to the
prediction of future cardiovascular outcomes across traditional
cardiovascular risk factors, as compared with brachial BP.Hao-Min Cheng, MD, PhD
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Achilles’ Heel of Statins?
Differences Between the New
Cholesterol Treatment Guidelines
and Everyday Clinical PracticeWe read with great interest the American College of Cardiology/
American Heart Association (ACC/AHA) new guidelines on the
treatment of blood cholesterol (1). The guidelines are based on a
thorough evaluation of randomized controlled trials (RCTs), sys-
temic reviews, and meta-analyses of RCTs with atherosclerotic
cardiovascular disease outcomes.
However, the issue of statin-related myopathy (SRM) has been
greatly underestimated, and this contrasts with ﬁndings of obser-
vational studies that suggest that SRM is relatively common (2,3).
The committee states that SRM is rare (w0.01 excess case per 100
statin-treated individuals per year), and this notion is derived
from data from RCTs that have systematically underestimated
SRM for several reasons (4):
1. Application of strict criteria to deﬁne myopathy, such as
creatine kinase (CK) elevation >10 upper limit normal
(ULN) with or without muscle symptoms, which is a rare
manifestation of myopathy. Therefore, the reported inci-
dence of myopathy in most trials was <0.3%, for example,
in the HPS (Heart Protection Study) study, it was 0.11%
(5); in the 4S (Scandinavian Simvastatin Survival Study)
study, 0.27% (6); and so on. Furthermore, in some trials,
myopathy was deﬁned as a persistent increase in CK >10
ULN on 2 consecutive measurements, which reduced even
more the incidence of myopathy. This is the case with the
TNT (Treating to New Targets) trial (7) in which none of
the participants, even on a high statin dose, fulﬁlled the
criteria for myopathy.
2. Failure to systematically report myalgias: in many trials,
patients were not interviewed for mild muscle complaints,
the commonest manifestation of myopathy, or for fatigue,
another form of myopathy.
3. Exclusion of patients most likely to suffer from myopathy,
such as patients with renal or liver insufﬁciency, patients
taking drugs with possible interaction with statins, older
patients, and so on.
4. Exclusion of patients experiencing muscle symptoms during
the open-label run-in phase of the trials. In some of them,
up to 30% of the eligible patients were excluded in pre-
randomization phases because they did not meet randomi-
zation criteria or had adverse events (7).
Observational studies report an incidence of SRM ranging be-
tween 5% and 10% (2,3), and this is consistent with our daily
clinical practice. It is therefore essential to emphasize that SRM is
not uncommon, and when it appears, does not always necessitates
statin discontinuation. In most cases, myalgias are mild, and after
careful clinical evaluation, discussion with the patient, and weigh-
ing the beneﬁts and risk, it is likely that the patient will remain
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Achilles’ Heel of Statins?
Differences Between the New
Cholesterol Treatment Guidelines
and Everyday Clinical PracticeThe American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) welcomes letters to inform its ongoing
work and encourages such correspondence about its guidelines.
Because the ACCF/AHA guideline development process is
rigorous and involves several layers of review by the writing com-
mittee, external peer reviewers, and participating organizations in
the document, it cannot respond to each issue raised after a
guideline has been published. The information, however, is for-
warded to the writing committee chair and oversight task forcefor review. If any issue is deemed by the ACCF/AHA to affect
patient safety, it will be considered immediately. Otherwise, the
information will be considered during the next update or revision
of the guideline.The American College of Cardiology
http://dx.doi.org/10.1016/j.jacc.2014.02.532Carotid Intima-Media
Thickness and Cardiovascular
Disease Risk Prediction
The 2013 American College of Cardiology and American Heart
Association guideline on the assessment of cardiovascular risk
gave a class III recommendation for carotid intima-media thick-
ness (IMT) testing (1). This assessment was based on an inac-
curate description of the clinical use of carotid IMT testing by
focusing only on the common carotid artery (CCA). The Amer-
ican Society of Echocardiography consensus statement (2) and
others have speciﬁed that carotid ultrasound for cardiovascular
disease risk prediction should be based on a thorough scan of the
carotid arteries for the presence of plaques, followed by mea-
surement of CCA IMT. This is because the presence and extent
of carotid plaque, which occurs predominantly in the carotid
bifurcation and internal carotid artery, rather than the CCA, are
independent predictors of future cardiovascular disease events
and in observational studies have performed better than CCA IMT
alone (3). The consensus statement, which has been widely adop-
ted, speciﬁcally stipulates that measuring CCA IMT without
considering plaque presence is not sufﬁcient; however, the evidence
that provided the working group with the “strongest evidence” for
its class III recommendation was a meta-analysis based solely on
CCA IMT (4).
The working group raised important concerns about stan-
dardization and measurement issues, but the clinical use of this
test has been standardized for more than 5 years (2) and has
published appropriate use criteria (5), and its reproducibility
is excellent, even in inexperienced hands. We believe that a
class IIb recommendation would be more appropriate, on the
basis of the test characteristics of carotid IMT plus plaque
scanning.
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